McGovern B, Garan H, Ruskin J N
Ann Intern Med. 1986 Jun;104(6):791-4. doi: 10.7326/0003-4819-104-6-791.
After the administration of verapamil for rapid tachycardias, five patients developed ventricular fibrillation or required urgent cardioversion. All episodes occurred in hospital emergency rooms, and each patient was resuscitated. Examination of electrocardiograms confirmed the presence of the Wolff-Parkinson-White syndrome. In four patients, the presenting tachyarrhythmia was atrial fibrillation with preexcited ventricular complexes, and in one patient a narrow QRS complex tachycardia was initially recorded. Acceleration of atrioventricular conduction occurred within 10 minutes of administration of verapamil, 5 to 10 mg intravenously. Subsequently, intracardiac electrophysiologic studies confirmed the presence of accessory atrioventricular pathways capable of rapid antegrade conduction in each patient. Because of this potentially fatal adverse response, verapamil should not be used in patients with atrial fibrillation and preexcited ventricular complexes.
在使用维拉帕米治疗快速性心动过速后,有5例患者发生了心室颤动或需要紧急心脏复律。所有发作均发生在医院急诊室,且每位患者均被复苏。心电图检查证实存在预激综合征。4例患者最初表现为房颤伴预激性心室复合波,1例患者最初记录为窄QRS波心动过速。静脉注射5至10毫克维拉帕米后10分钟内发生房室传导加速。随后,心内电生理研究证实每位患者均存在能够快速前向传导的房室旁道。由于这种潜在的致命不良反应,维拉帕米不应应用于房颤伴预激性心室复合波的患者。